Investigation of Receptor Heteromers Using NanoBRET Ligand Binding

Elizabeth K. M. Johnstone 1,2,3,*, Heng B. See 1,2,3, Rekhati S. Abhayawardana 1,2,3, Angela Song 4, K. Johan Rosengren 4, Stephen J. Hill 1,2,5,6, and Kevin D. G. Pfleger 1,2,3,7,8,*

1. Introduction

Receptor heteromerization is the formation of a complex composed of two (or more) functional receptor units. Although the constituent receptors are functional in their own right as monomers/homomers, the formation of a heteromer results in a complex that may have distinct biochemical properties [1]. This attainment of novel heteromer pharmacology expands the complexity of receptor signaling networks and adds selectivity and specificity to receptor signaling. Although this makes receptor heteromers exciting potential drug targets, to date only modest progress has been made towards therapeutically targeting these complexes. One reason for this is the difficulty in detecting heteromers and monitoring their pharmacology. In particular, differentiating heteromer-specific pharmacology from monomer/homomer-specific pharmacology can be a major challenge. In order to address this issue, we have developed the Receptor-Heteromer Investigation Technology (Receptor-HIT) [2,3], which has been used to investigate several G protein-coupled receptor (GPCR)
heteromers [2,4–11]. In addition, the Receptor-HIT assay has been used to characterize receptor tyrosine kinase (RTK) heteromers [12], as well as heteromers composed of both GPCRs and RTKs [13–15] or a GPCR and the Receptor for Advanced Glycation End-products [16].

The Receptor-HIT assay enables rapid identification, screening and profiling of receptor heteromers through ligand-dependent modulation of interactions between the receptors and specific biomolecules. The assay uses a proximity-based reporter system, such as bioluminescence resonance energy transfer (BRET), which allows the proximity between the receptors and the interacting biomolecules to be monitored. Previously, the interacting biomolecules used in Receptor-HIT studies have been intracellular proteins (Figure 1a), enabling functional interactions to be identified. However, as we have previously discussed [17], Receptor-HIT can also be configured to investigate heteromers at their extracellular surface, with the use of a fluorescent ligand as the labeled interacting biomolecule (Figure 1b).

**Figure 1.** Intracellular and extracellular Receptor-Heteromer Investigation Technology (Receptor-HIT) assay. Receptor-HIT allows for investigation of receptor heteromers through ligand-dependent modulation of interactions between receptors and specific biomolecules. The Receptor-HIT assay uses a proximity-based reporter system such as bioluminescence or fluorescence resonance energy transfer (BRET or FRET) or protein complementation. The assay has most commonly been used to investigate GPCR heteromers (GPCR-HIT) [2] however it can be used to investigate any type of heteromers, such as RTK heteromers (RTK-HIT) [12]. The assay works by coexpressing each receptor in cells, one receptor tagged with the first reporter component of the proximity assay (RC1), such as a BRET donor, and the other receptor untagged with respect to the proximity assay system. Instead, an interacting biomolecule is tagged with the second reporter component (RC2), such as a BRET acceptor. Usually, this interacting biomolecule is a coexpressed intracellular protein (a) however it can also be a labeled ligand (b). The assay works by adding a ligand that is selective for the untagged receptor. If this results in modulation of the proximity signal between the tag on the receptor and the tag on the interacting biomolecule, this indicates heteromerization of the two receptors.
Recently, we have developed the NanoBRET ligand binding assay [18–23], in which we have successfully monitored binding of fluorescent ligands to Nanoluciferase (Nluc)-tagged GPCRs. In the present study, we have demonstrated the Receptor-HIT assay utilizing NanoBRET ligand binding to investigate two GPCR heteromers: between the angiotensin II type 1 (AT\textsubscript{1}) receptor and the β\textsubscript{2} adrenergic receptor (AT\textsubscript{1}-β\textsubscript{2}AR heteromer), as well as between the AT\textsubscript{1} and angiotensin II type 2 receptor (AT\textsubscript{1}-AT\textsubscript{2}R heteromer). These three receptors and the hormones that target them have functions in many different physiological systems, and in particular, they have fundamental roles in the maintenance of cardiovascular homeostasis. AT\textsubscript{1}-β\textsubscript{2}AR heteromers have been described in several studies [9,24,25] and are involved in the mediation of cardiomyocyte contractility and heart rate in intact mice [24]. The pharmacology of the AT\textsubscript{1}-AT\textsubscript{2}R heteromer has been extensively studied [4,26–35], and most recently, has been implicated in Parkinson’s disease [27].

2. Results

2.1. AT\textsubscript{1}-β\textsubscript{2}AR Heteromer

The first heteromer that we investigated was between the AT\textsubscript{1} receptor and the β\textsubscript{2}AR. Several studies have investigated this heteromer in a variety of systems, and reported evidence for it being a constitutive heteromer that displays modulated G protein signaling and β-arrestin recruitment [9,24,25]. To investigate this complex we first looked at binding of a BODIPY-630/650 tagged angiotensin II ligand (BODIPY-AngII) to the N-terminally Nluc-tagged AT\textsubscript{1} receptor (Nluc-AT\textsubscript{1}; Figure 2a) using the NanoBRET ligand binding assay [18–21]. We were able to demonstrate saturable binding of BODIPY-AngII to the AT\textsubscript{1} receptor, which was substantially reduced by treatment with a high concentration of the AT\textsubscript{1} antagonist olmesartan (Figure 2b), enabling generation of a BODIPY-AngII specific binding curve (Figure 2c). To confirm the specificity of our BODIPY-AngII ligand we next conducted the saturation assay in cells expressing N-terminally Nluc-tagged β\textsubscript{2}AR (Nluc-β\textsubscript{2}AR) in the presence and absence of the β\textsubscript{2}AR antagonist propranolol (Figure 2d). Here we saw there was no displacement of BODIPY-AngII binding in the presence of propranolol (Figure 2e) and therefore no specific binding of BODIPY-AngII to Nluc-β\textsubscript{2}AR (Figure 2f). In contrast, when we coexpressed the untagged AT\textsubscript{1} receptor with Nluc-β\textsubscript{2}AR, using the Receptor-HIT assay configuration (Figure 2g), we observed displacement of BODIPY-AngII binding in the presence of olmesartan (Figure 2h) resulting in clear, saturable, specific binding of BODIPY-AngII (Figure 2i). It is important to note here the difference in scale of the y-axis, as the BODIPY-AngII-induced BRET signal is approximately ten times stronger between BODIPY-AngII and AT\textsubscript{1} receptors than BODIPY-AngII and AT\textsubscript{1}-β\textsubscript{2}AR heteromers. This is most likely due to the increased distance between BODIPY-AngII bound to AT\textsubscript{1} and Nluc-labeled β\textsubscript{2}AR across the AT\textsubscript{1}-β\textsubscript{2}AR heteromer, compared to BODIPY-AngII bound to Nluc-labeled AT\textsubscript{1} receptors. This specific and saturable binding of BODIPY-AngII in cells expressing Nluc-β\textsubscript{2}AR + AT\textsubscript{1} confirms the close proximity of the AT\textsubscript{1} receptor and β\textsubscript{2}AR in our system. Interestingly, when we compared the affinity of BODIPY-AngII binding in the two systems, we saw a small but significant decrease in the affinity of binding to AT\textsubscript{1}-β\textsubscript{2}AR heteromers when compared to binding to AT\textsubscript{1} receptors (mean $K_d \pm \text{SEM} = 338.4 \pm 57.4$ nM vs. $114.1 \pm 9.9$ nM, respectively; $n = 4$, $p < 0.05$ for unpaired t-test). Consistent with the lack of propranolol displacement by BODIPY-AngII, when we conducted the NanoBRET assay using cells transfected with only Nluc-β\textsubscript{2}AR and treated with BODIPY-AngII in the presence or absence of olmesartan (Figure 2j), no statistically significant specific binding of BODIPY-AngII was observed (Figure 2k,l).
Figure 2. Saturation binding of BODIPY-AngII to the AT$_1$ receptor and the AT$_1$-$\beta_2$AR heteromer. Cells expressing Nluc-AT$_1$ (a–c) or Nluc-$\beta_2$AR (d–f,j–l) or Nluc-$\beta_2$AR + AT$_1$ (g–i) were treated with BODIPY-AngII (B-AngII) in the presence or absence of 1 µM olmesartan (Olm; a–c,g–l) or the presence or absence of 10 µM propranolol (Prop; d–f) to generate BODIPY-AngII total and non-specific binding data (b,e,h,k) and specific binding curves (where possible; c,f,i,l). Data are displayed as the raw BRET ratio (b,e,h,k) or specific binding (c,f,i,l), mean ± SEM of three (e,f) or four (b,c,h,i,k,l) independent experiments.

Although cells expressing Nluc-AT$_1$ (Figure 2b) and Nluc-$\beta_2$AR + AT$_1$ (Figure 2h) displayed saturable binding of BODIPY-AngII that could be displaced by olmesartan, there still appeared to be a saturable component to the BODIPY-AngII binding that was not displaced by olmesartan. This saturable binding is likely due to the presence of a non AT$_1$ receptor AngII-binding site, and as to our knowledge the AT$_2$ receptor is not endogenously expressed in HEK293 cells, this binding site may be a non-AT$_1$, non-AT$_2$ receptor AngII-
binding site that has previously been detected in HEK293 cells [36]. Wangler et al. [36] observed saturable binding of 125I-AngII in HEK293 cells, which could not be displaced by either AT1 or AT2 receptor blockade, and they identified this non-AT1, non-AT2 receptor AngII-binding site as the membrane-bound variant of metalloendopeptidase neurolysin. It is possible that in our assays this protein is in sufficiently close proximity to Nluc-AT1 (Figure 2b) or Nluc-β2AR + AT1 (Figure 2h) to produce a NanoBRET signal and saturable BODIPY-AngII binding not able to be displaced by olmesartan.

To confirm the specificity of the NanoBRET signal, we investigated binding of BODIPY-AngII in cells expressing a Nluc-tagged GPCR not known to heteromerize with the AT1 receptor, the cholecystokinin CCK1 receptor. In contrast to the specific binding we observed in Nluc-β2AR + AT1 cells, we did not observe specific binding of BODIPY-AngII in cells expressing Nluc-CCK1 + AT1 (Figure 3a). This lack of specific binding was unlikely to be due to decreased expression of Nluc-CCK1 compared to Nluc-β2AR, as there was no significant difference observed between the luminescence produced by both sets of cells (Figure 3b). Additionally, the lack of specific binding in Nluc-CCK1 + AT1 cells was unlikely to be due to decreased expression of the AT1 receptor, as there was no significant difference in the level of IP1 produced between the two sets of cells upon stimulation with AngII (Figure 3c). Thus, this indicates that the specific binding observed in Nluc-β2AR + AT1 cells is due to binding of BODIPY-AngII to AT1 receptors heteromerized with Nluc-β2AR, and not due to overcrowding of receptors at the plasma membrane.

Figure 3. Lack of Receptor-Heteromer Investigation Technology (Receptor-HIT) signal between AT1 and CCK1. Cells were transfected with Nluc-β2AR + AT1 or Nluc-CCK1 + AT1. In the NanoBRET ligand binding assay (a), cells were treated with 1 μM BODIPY-AngII in the presence or absence of 1 μM olmesartan to enable calculation of BODIPY-AngII specific binding. In the luminescence assay (b), raw luminescence values were obtained from untreated aliquots of cells. In the IP1 assay (c), cells were treated with 1 μM AngII. Significant differences (*) were observed in (a) but not (b) or (c), using unpaired t-tests. Data are displayed as mean ± SEM of three independent experiments.

We next wanted to see if we could also detect binding at AT1-β2AR heteromers using a BRET competition binding assay. In cells expressing Nluc-β2AR + AT1 there was clear binding of BODIPY-AngII, which could be displaced by increasing concentrations of olmesartan (Figure 4). This confirmed that the NanoBRET ligand binding assay could be run successfully as a competition assay as well as a saturation assay.

We then wanted to investigate the results of the AT1-β2AR heteromer ligand binding assay when it was conducted in the reverse configuration. For these assays we used a BODIPY-630/650 tagged propranolol ligand (BODIPY-propranolol). When we investigated binding to Nluc-β2AR (Figure 5a), we observed saturable binding of BODIPY-propranolol that could be completely displaced by unlabeled propranolol (Figure 5b), enabling generation of a BODIPY-propranolol specific binding curve (Figure 5c). When we conducted the assay using cells expressing Nluc-AT1 (Figure 5d), we did not observe specific binding of BODIPY-propranolol to the AT1 receptor that was sensitive to displacement by olme-
sartan (Figure 5e,f). Next, we conducted the assay using the Receptor-HIT configuration, with cells expressing Nluc-AT$_1$ + β$_2$AR (Figure 5g). Here we observed displacement of BODIPY-propranolol binding in the presence of unlabeled propranolol (Figure 5h) resulting in generation of a BODIPY-propranolol specific binding curve (Figure 5i), confirming the close proximity of the two receptors in our system. Similar to what we observed in the previous configuration (Nluc-β$_2$AR + AT$_1$), the BODIPY-propranolol-induced BRET signal between BODIPY-propranolol and β$_2$AR was approximately ten times stronger than between BODIPY-propranolol and AT$_1$-β$_2$AR heteromers, again likely due to the increased distance when BODIPY-propranolol binds to β$_2$ARs that are heteromerized with Nluc-AT$_1$. Interestingly, and similar to what was observed in the previous configuration, when we compare the affinity of BODIPY-AngII binding in the two systems, we see a small but significant decrease in the affinity of binding to AT$_1$-β$_2$AR heteromers when compared to binding to β$_2$ARs (mean $K_d$ ± SEM = 8.8 ± 4.0 nM n = 8 vs. 3.9 ± 0.5 nM n = 4, respectively; $p < 0.05$ for unpaired t-test).

As with the previous configuration, we needed to confirm that the Receptor-HIT signal we observed was not due to overcrowding of receptors at the cell surface. Again we used a control receptor, this time the TRPC6 transient receptor potential channel 6 (TRPC6). Here we saw that there was no specific binding of BODIPY-propranolol in cells expressing Nluc-TRPC6 + β$_2$AR (Figure 6a), unlike cells expressing Nluc-AT$_1$ + β$_2$AR. This lack of signal was unlikely to be due to a reduced expression of Nluc-TRPC6 relative to Nluc-AT$_1$, as there was no significant difference in the levels of luminescence produced (Figure 6b). Nor was the lack of signal likely to be due to reduced expression of β$_2$AR, as there was no significant difference in the level of isoprenaline-induced cAMP production by both sets of cells (Figure 6c). Thus, this indicates that the specific binding observed in Nluc-AT$_1$ + β$_2$AR cells is due to binding of BODIPY-propranolol to β$_2$ARs that form heteromers with Nluc-AT$_1$, and not due to overcrowding of receptors at the plasma membrane.

![Figure 4](image-url)  
**Figure 4.** Competition binding of BODIPY-AngII to the AT$_1$-β$_2$AR heteromer. Cells expressing Nluc-β$_2$AR + AT$_1$ were treated with 500 nM BODIPY-AngII in the presence of increasing concentrations of olmesartan. Data are normalized (100% being vehicle-treated and 0% being 1 μM olmesartan-treated) and displayed as relative BRET ratio, mean ± SEM of four independent experiments.
Figure 5. Saturation binding of BODIPY-propranolol to the β$_2$AR and the AT$_1$-β$_2$AR heteromer. Cells expressing Nluc-β$_2$AR (a–c) or Nluc-AT$_1$ (d–f) or Nluc-AT$_1$ + β$_2$AR (g–i) were treated with BODIPY-propranolol (B-Prop) in the presence or absence of 10 μM propranolol (Prop; a–c,g–i) or the presence or absence of 1 μM olmesartan (Olm; d–f) to generate BODIPY-propranolol total and non-specific binding data (b,e,h) and specific binding curves (where possible; c,f,i). Data are displayed as the raw BRET ratio (b,e,h) or specific binding (c,f,i), mean ± SEM of three (e,f), four (b,c) or eight (h,i) independent experiments.

Figure 6. Lack of Receptor-Heteromer Investigation Technology (Receptor-HIT) signal with β$_2$AR and TRPC6. Cells were transfected with Nluc-AT$_1$ + β$_2$AR or Nluc-TRPC6 + β$_2$AR. In the BRET ligand binding assay (a), cells were treated with 80 nM BODIPY-propranolol in the presence or absence of 10 μM propranolol to enable calculation of BODIPY-propranolol specific binding. In the luminescence assay (b), raw luminescence values were obtained from untreated aliquots of cells. In the cAMP assay (c), cells were treated with 10 μM isoprenaline (iso). Significant differences (*) were observed in (a) but not (b,c), using unpaired t-tests. Data are displayed as mean ± SEM of three independent experiments.
Finally, we wanted to investigate if there were any changes to the binding of BODIPY-propranolol when the AT$_1$ protomer of the AT$_1$-β$_2$AR heteromer was bound by a selective ligand. To do this, we investigated the effects of various AT$_1$ receptor ligands on propranolol-induced displacement of BODIPY-propranolol binding in a competition assay (Figure 7a). This showed that there was no significant change in the pIC$_{50}$ values of displacement of BODIPY-propranolol bound to AT$_1$-β$_2$AR heteromers (Figure 7a and Table 1) or β$_2$AR protomers (Figure 7b and Table 1).

**Figure 7.** Competition binding of BODIPY-propranolol to β$_2$AR and the AT$_1$-β$_2$AR heteromer. Cells expressing Nluc-AT$_1$ + β$_2$AR (a) or Nluc-β$_2$AR (b) were treated with 50 nM BODIPY-propranolol in the presence of various AT$_1$ ligands (1 µM) and increasing concentrations of propranolol. Data are normalized to vehicle treatment for that transfection (0% being 10 µM propranolol-treated and 100% being vehicle only treated) and displayed as relative BRET ratio, mean ± SEM of four independent experiments.

**Table 1.** pIC$_{50}$ values from competition curves in Figure 7. No significant differences were observed within each transfection using one-way ANOVA.

|                | Vehicle | AngII | Olmesartan | Candesartan | SII | Trv027 |
|----------------|---------|-------|------------|-------------|-----|--------|
| Nluc-AT$_1$ + β$_2$AR | 7.96 ± 0.18 | 7.94 ± 0.31 | 7.91 ± 0.26 | 7.92 ± 0.32 | 7.98 ± 0.31 | 7.88 ± 0.35 |
| Nluc-β$_2$AR       | 8.17 ± 0.02 | 8.14 ± 0.02 | 8.06 ± 0.02 | 8.10 ± 0.04 | 8.16 ± 0.11 | 8.12 ± 0.05 |

2.2. AT$_1$-AT$_2$ Heteromer

In addition to the AT$_1$-β$_2$AR heteromer, we also used the NanoBRET ligand binding assay to investigate heteromer formation between the AT$_1$ receptor and the AT$_2$ receptor, both of which bind AngII. This heteromer has been well characterized in numerous systems, and has been shown to cause alterations to receptor signaling, β-arrestin recruitment and trafficking [4,26–35]. We investigated this heteromer by first looking at binding of various concentrations of a TAMRA-labeled AngII (TAMRA-AngII) to Nluc-AT$_1$ in a competition binding assay with olmesartan (Figure 8a). Here we observed displacement of TAMRA-
AngII bound to Nluc-AT1 with olmesartan (Figure 8b). We then conducted a similar assay using the AT2 selective antagonist PD 123319 (Figure 8c), and this time we were unable to see any displacement of bound TAMRA-AngII (Figure 8d). Finally, we conducted the assay in the Receptor-HIT configuration to look for proximity between the two receptors, by coexpressing Nluc-AT1 with the untagged AT2 receptor (Figure 8e). However, due to the non-selectivity of the TAMRA-AngII ligand we needed to block the Nluc-tagged AT1 receptors to prevent their binding of TAMRA-AngII. To do this we treated the cells with 1 µM olmesartan, the concentration at which we saw complete displacement of TAMRA-AngII binding previously (Figure 8b). In addition to olmesartan, cells were treated with TAMRA-AngII and increasing concentrations of PD 123319, to see if we were able to observe binding of TAMRA-AngII that could be displaced by PD 123319. This was indeed the case (Figure 8f), thus confirming that TAMRA-AngII binding was occurring specifically at AT2 receptors, and not AT1 receptors. This indicated that Nluc-AT1 was proximal to TAMRA-AngII-bound AT2 receptors, again confirming that the Receptor-HIT assay could be used successfully to monitor receptor heteromers at their extracellular surface.

Figure 8. Competition binding of TAMRA-AngII to the AT1 receptor and the AT1-AT2 heteromer. Cells expressing Nluc-AT1 and treated with various concentrations of TAMRA-AngII (T-AngII) as stated, with increasing concentrations of olmesartan (Olm) (a,b). Cells expressing Nluc-AT1 and treated with various concentrations of TAMRA-AngII as stated, with increasing concentrations of PD 123319 (PD) (c,d). Cells expressing Nluc-AT1 and untagged AT2 and treated with 1 µM olmesartan, various concentrations of TAMRA-AngII as stated, and increasing concentrations of PD 123319 (e,f). Data are normalized (100% being 100 nM TAMRA-AngII treated with no competitor present and 0% being 1 nM TAMRA-AngII treated at maximum competitor concentration) and displayed as relative BRET ratio, mean ± SEM of three independent experiments.
Finally, we repeated the assay in the reverse configuration. Here, Nluc-AT$_2$ was coexpressed with the untagged AT$_1$ receptor, and we used 100 µM PD 123319 to block Nluc-AT$_2$ (Figure 9a). Treatment with TAMRA-AngII, and increasing concentrations of olmesartan showed displacement of TAMRA-AngII bound specifically to AT$_1$ receptors (Figure 9b). This indicated the close proximity of AT$_1$ receptors to Nluc-AT$_2$, and confirmed that the assay could be used successfully in both configurations.

**Figure 9.** Competition binding of TAMRA-AngII to the AT$_1$-AT$_2$ heteromer. Cells expressing Nluc-AT$_2$ and untagged AT$_1$ (a) were treated with 100 µM PD 123319 (PD), 1 µM TAMRA-AngII (T-AngII) and increasing concentrations of olmesartan (Olm) (b). Data are normalized (100% being vehicle treated and 0% being 1 µM olmesartan treated) and displayed as relative BRET ratio, mean ± SEM of three independent experiments.

### 3. Discussion

In this study we have successfully adapted the NanoBRET ligand binding assay to investigate heteromers using the Receptor-HIT configuration. This demonstrates broadening of the applicability of Receptor-HIT using BRET, so that it can now be used to provide information about heteromer ligand binding, as well as heteromer interactions with intracellular proteins.

Traditionally, evidence for GPCR heteromerization from ligand binding studies has come from radioligand binding assays that reveal ligand cooperativity upon coexpression of the two receptors of interest [37]. Indeed, there are numerous examples of studies providing evidence for GPCR oligomers that display either positive [38–40] or negative [41–44] ligand cooperativity. While this approach enables elucidation of functional consequences of oligomerization, careful interpretation of the data is required to ensure the observed results are actually a consequence of heteromer-mediated cooperativity. For example, as GPCRs can have different affinities for ligands when they are bound to G proteins, dual receptor activation could limit the supply of G proteins, leading to altered ligand affinities and thus false ligand cooperativities [37]. Furthermore, assessment of ligand cooperativity does not provide direct evidence for proximity between receptors, and nor will it enable identification of ligand interactions with neutral cooperativity. The Receptor-HIT ligand binding assay overcomes these limitations as it is able to detect heteromers based on receptor proximity, not solely on ligand cooperativity. Additionally, using a proximity assay such as BRET with fluorescent ligands overcomes all of the issues associated with the use of radiolabeled ligands, which are costly, time consuming to use, require numerous measures to monitor and minimize exposure to radioactivity when carrying out the assays, and generate radioactive waste that requires appropriate disposal.

Previously, the Receptor-HIT approach using time resolved fluorescence resonance energy transfer (TR-FRET) has been utilized to investigate ligand binding to the dopamine D$_1$-D$_2$ heteromer. Hounsou et al. [45] coexpressed SNAP-tag-labeled D$_1$ receptors (SNAP-D$_1$) with D$_3$ receptors, and treated with a fluorescent D$_3$ receptor-selective ligand. This approach worked well and they were able to measure TR-FRET between SNAP-D$_1$ and the fluorescent ligand bound to the D$_3$ receptor. Furthermore, these investigators were able
to confirm that the fluorescent ligand was binding specifically to the D₃ receptor through displacement with D₃ selective ligands. While both the TR-FRET and our BRET approach were successful, our technique has one significant advantage over TR-FRET. Although both assays require the addition of substrates for the energy donor (furimazine for Nluc and SNAP-Lumi4-Tb for TR-FRET [46]), the TR-FRET method requires removal of the SNAP-tag substrate and several wash steps. In contrast, the BRET assay can be performed in a completely homogenous manner, reducing time and potential introduction of error that can occur through multiple wash steps.

Extending its application beyond in vitro systems, NanoBRET has now also been used to visualize ligand binding to a GPCR in vivo. MDA-MB-231 triple-negative human breast cancer cells stably expressing Nluc-β₂AR were injected into a mammary fat pad of a mouse [47]. Once the tumor size reached over 200 mm³, BRET ratios indicating ligand binding were determined following administration of BODIPY-propranolol. Future studies could potentially use the Receptor-HIT configuration with such an approach to investigate receptor heteromers in vivo.

More recently, NanoBRET ligand binding has been demonstrated at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing [21]. Again, such an approach could enable the Receptor-HIT ligand binding assay to be utilized for GPCRs under endogenous promotion, as has already been done for Receptor-HIT using proximity to the intracellular β-arrestin molecule, albeit when the arrestin and the second receptor were exogenously expressed [10].

Proximity ligation assays are an alternative to BRET, and have been used to visualize protein–protein interactions in primary tissue, including investigating heteromerization of GPCRs [48–50]. However, these assays require well-validated antibodies, which are not always available for GPCRs in particular [17].

The AT₁-β₂AR heteromer ligand binding assay revealed that there was a far greater level of BRET produced when the fluorescent ligand was bound directly to the Nluc-tagged receptor than when the fluorescent ligand was bound to the untagged receptor complexed with the Nluc-tagged receptor. The major cause of this increase is likely to be due to the difference in distance between the BRET donor and acceptor. BRET efficiency is inversely proportional to the distance between the donor and acceptor molecules to the sixth power, resulting in energy transfer that occurs over distances of less than about 10 nm [51,52]. As GPCRs are estimated to be ~4 nm in diameter [53], this highlights the sensitivity of the BRET assay at detecting small changes in proximity between donor and acceptor molecules. Another potential contributing factor to the increased level of BRET in the monomer/homomer assay is that the proportion of heteromers in the system may be lower than monomers/homomers. Although most studies suggest that GPCRs display a similar propensity to form homomers or heteromers [54], there are examples of receptors that reportedly have greater [55,56] or lesser [57,58] proclivity to form homomers relative to heteromers.

The results of this study showed a decrease in affinity of both fluorescent ligands when bound to receptors within the AT₁-β₂AR heteromer when compared to either receptor alone. This suggests that the unbound receptor within the heteromer may be allosterically modulating the bound receptor, causing a reduction in the affinity of the fluorescent ligand. This is a novel finding for the AT₁-β₂AR heteromer, as ligand binding has not been previously investigated for this complex.

As well as the AT₁-β₂AR heteromer, we were also able to successfully use the heteromer ligand binding assay to investigate the AT₁-AT₂ heteromer. As the TAMRA-AngII ligand could bind to both receptors, this assay required a more complicated set up, with the Nluc-labeled receptor blocked from TAMRA-AngII binding with the use of a selective antagonist. Nevertheless, we were still able to clearly see binding of TAMRA-AngII to the unlabeled receptor, indicating its heteromerization with the Nluc-tagged receptor. It should be noted however, that ligand binding to one receptor may allosterically alter binding
affinity to the second receptor within the heteromer, and this should therefore be taken into consideration when calculating ligand affinities with this assay set up.

In conclusion, we have demonstrated that the Receptor-HIT assay can be used with the NanoBRET ligand binding assay to detect receptor heteromerization. We have successfully monitored the proximity between receptors within the AT₁-β₂AR heteromer and the AT₁-AT₂ heteromer, the latter being a complex that can be interrogated with a non-selective fluorescent ligand with the additional use of unlabeled selective antagonists. We have also demonstrated that this real-time, live cell, non-radioactive assay is sensitive enough to perform completely homogenously, further increasing its exciting potential for drug discovery and profiling.

4. Materials and Methods

4.1. cDNA Constructs

Nluc-β₂AR [18], Nluc-AT₁ [18] and Nluc-CCK₁ were from Promega (Madison, WI, USA). Nluc-TRPC6 was generated by GeneArt (Thermo Fisher Scientific, Regensburg, Bavaria, Germany). Nluc-AT₂ was generated by inserting the AT₂ coding region (obtained from the Missouri S&T cDNA Resource Center (Rolla, MO, USA) into a pcDNA3.Nluc vector generated in house (containing the IL6 signal peptide upstream to Nluc). The β₂AR construct was from the Missouri S&T cDNA Resource Center. The human AT₁ and AT₂ receptor constructs used were generated by inserting the AT₁ or AT₂ coding region (obtained from the Missouri S&T cDNA Resource Center) after the mGluR5 signal peptide and FLAG-tag coding region in a pcDNA3 construct made in house.

4.2. Ligands, and Generation of BODIPY-AngII

TAMRA-AngII was from AnaSpec (Fremont, CA, USA), BODIPY-propranolol (CA200689) was from Hello Bio (Bristol, UK), olmesartan medoxomil was from Zhou Fang Pharm Chemical (Shanghai, China) and Sigma Aldrich (Castle Hill, NSW, Australia). AngII, candesartan cilexetil and PD 123319 were from Sigma Aldrich.

BODIPY-AngII [19], SII and Trv0027 were made by solid phase peptide synthesis. The amino acid sequence for each peptide was assembled on 2-chlorotrityl resin (0.8 mmol/g loading) using standard Fmoc chemistry with HBTU/DIEA activation. Briefly, 2-chlorotrityl resin was swelled in dichloromethane (DCM) for 1 h, then 2 equiv of Fmoc-protected C-terminal amino acid with 8 equiv of DIEA were added to the resin and allowed to react for 30 min. Unreacted sites were blocked with DCM/MeOH/DIEA (17:2:1). The N-terminal Fmoc protection group was removed with 20% piperidine in dimethylformamide (2 × 5 min). All remaining couplings were performed on a CS Bio CS336X automated synthesizer with 4 equiv of Fmoc-amino acid, 8 equiv of HBTU and 8 equiv of DIEA. The peptide was cleaved from the resin with TFA/TIPS/Milli Q (95:2.5:2.5) and lyophilized. The crude peptide was dissolved in 10% acetonitrile and purified by RP-HPLC on a Prominence HPLC system (Shimadzu) using a semipreparative Grace Vydac C18 column (250 mm × 10 mm, 10 µm) at a 1% gradient and a flow rate of 3 mL/min. Electrospray mass spectrometry (AB Sciex) was used to confirm the molecular weight. For N-terminal labeling the pure lyophilized AngII was dissolved in DMF at 1 mM concentration with 100 mM trimethylamine and 1 mM of BODIPY™ 630/650-nX NHS ester (Thermo Fisher Scientific, Brisbane, Australia), and stirred for 24 h, protected from light. The labeling reaction was monitored with analytical RP-HPLC and electrospray mass spectrometry.

4.3. Cell Culture and Transfection

HEK293FT cells were maintained at 37 °C, 5% CO₂ in complete medium (Dulbecco’s modified Eagle’s medium (DMEM) containing 0.3 mg/mL glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin) supplemented with 10% fetal calf serum (FCS) (GIBCO BRL, Carlsbad, CA, USA). Transient transfections were carried out directly in a 96-well plate using FuGENE 6 (Promega) according to the manufacturer’s instructions. The cDNA transfection mix was added to 100,000 cells/well in DMEM supplemented with 10%
Cells were then incubated at 37 °C, 5% CO2, and assays were carried out 48 h post transfection.

4.4. NanoBRET Saturation Ligand Binding Assays

Saturation ligand binding assays (Figures 2, 3, 5 and 6) were conducted by firstly removing the media and replacing with vehicle (HBSS) or competitor ligand diluted in HBSS. This was incubated for 20 min at 37 °C, 5% CO2 and then the fluorescent ligands diluted in HBSS were added and incubated for a further 40 min. Furimazine (10 µM) was then added and luminescence was measured immediately at 37 °C using the LUMIstar plate reader (BMG Labtech, Mornington, VIC, Australia) with 450 nm (80-nm bandpass) and >610 nm (longpass). The raw BRET ratio was calculated by dividing the long wavelength emission by the short wavelength emission. Non-specific binding was determined in the presence of 1 µM olmesartan or 10 µM propranolol as indicated. Specific binding was then calculated by subtracting the raw BRET ratio of the competitor-treated sample (non-specific binding) from the raw BRET ratio of the vehicle treated sample (total binding). All individual experiments were conducted with duplicate wells.

4.5. NanoBRET Competition Ligand Binding Assays

Competition ligand binding assays (Figures 4 and 7–9) were conducted by firstly removing the media and replacing with vehicle (HBSS) or competitor ligand(s) diluted in HBSS. This was incubated for 20 or 30 min at 37 °C, 5% CO2 and then the fluorescent ligands diluted in HBSS were added and incubated for a further 30 or 40 min. Furimazine (10 µM) was then added and luminescence was measured immediately at 37 °C using either the PHERAstar FS plate reader (BMG Labtech) with 460 nm (80-nm bandpass) and >610 nm (longpass) or the LUMIstar plate reader (BMG Labtech) with 450 nm (80-nm bandpass) and >610 nm (longpass). The relative BRET ratio was calculated by normalizing the data, as described in the figure legends. All individual experiments were conducted with duplicate wells.

4.6. Inositol Monophosphate (IP1) Accumulation Assays

Measurement of IP1 accumulation was performed using the IP-One Tb kit (Cisbio Bioassays (PerkinElmer), Codolet, Occitania, France) according to the manufacturer’s instructions. Cells were treated for 30 min at 37 °C with AngII or vehicle. The cells were then lysed by adding the supplied assay reagents, and the assay was incubated for 1 h at room temperature. Fluorescence was measured at 620 nm and 665 nm, 50 µs after excitation at 340 nm using the EnVision 2102 multilabel plate reader (PerkinElmer, Glen Waverley, VIC, Australia).

4.7. cAMP Accumulation Assays

Measurement of cAMP accumulation was performed using the cAMP dynamic 2 assay kit (Cisbio Bioassays) according to the manufacturer’s instructions. Cells were treated for 30 min at 37 °C with isoprenaline or vehicle. The cells were then lysed by adding the supplied assay reagents, and the assay was incubated for 1 h at room temperature. Fluorescence was measured at 620 nm and 665 nm, 50 µs after excitation at 340 nm using the EnVision 2102 multilabel plate reader (PerkinElmer).

4.8. Data Presentation and Statistical Analysis

All data were presented and analyzed using GraphPad Prism 8.0. Saturation binding data were fitted with one-site nonlinear regression for specific binding. Competition binding data were fitted using logarithmic nonlinear regression (three parameter). Statistical analysis was performed as described in the relevant figure/table legends or in the text, with p < 0.05 considered significant.
Author Contributions: E.K.M.J., H.B.S. and R.S.A. conducted the experiments and analyzed the results. A.S. and K.J.R. synthesized the BODIPY-AngII. E.K.M.J. and K.D.G.P. conceived the experiments and wrote the paper. S.J.H. provided input into study design. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded in part by Australian Research Council (ARC) Linkage Grants LP130100037 and LP160100857, with The University of Nottingham, Promega, BMG Labtech and Dimerix providing funding as partner organizations. K.D.G.P. received fellowship support from the National Health and Medical Research Council (NHMRC) of Australia (RD Wright Biomedical Research Fellowship, 1085842) and K.J.R. was supported by an ARC Future Fellowship (FT130100890). E.K.M.J. was supported for part of this work by the Richard Walter Gibbon Medical Research Scholarship from The University of Western Australia, and latterly by an ARC Centre for Personalised Therapeutics Technologies (IC170100016) postdoctoral fellowship. K.D.G.P. is Deputy Director of this Centre. S.J.H. thanks the Raine Foundation for a Visiting Research Professorship to The University of Western Australia.

Institutional Review Board Statement: Not applicable as this study did not involve humans or animals.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest: E.K.M.J., H.B.S., R.S.A., A.S., K.J.R. have nothing to disclose. K.D.G.P. has received funding from Promega, BMG Labtech and Dimerix as Australian Research Council Linkage Grant participating organizations. These organizations played no role in any aspect of the conception or design of the research, collection, analysis and interpretation of results, or writing and editing of the manuscript. S.J.H. also received funding from Promega associated with a BBSRC Link grant. K.D.G.P. is Chief Scientific Advisor of Dimerix, of which he maintains a shareholding. Dimerix has proprietary rights to the Receptor-HIT assay.

References
1. Ferre, S.; Baler, R.; Bouvier, M.; Caron, M.G.; Devi, L.A.; Durroux, T.; Fuxe, K.; George, S.R.; Javitch, J.A.; Lohse, M.J.; et al. Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol. 2009, 5, 131–134. [CrossRef] [PubMed]
2. See, H.B.; Seeger, R.M.; Kocan, M.; Eidne, K.A.; Pfleger, K.D.G. Application of G protein-coupled receptor-heteromer identification technology to monitor β-arrestin recruitment to G protein-coupled receptor heteromers. Assay Drug Dev. Technol. 2011, 9, 21–30. [CrossRef] [PubMed]
3. Johnstone, E.K.M.; Pfleger, K.D.G. Receptor-Heteromer Investigation Technology and its application using BRET. Front. Endocrinol. 2012, 3, 101. [CrossRef] [PubMed]
4. Porrello, E.R.; Pfleger, K.D.; Seeger, R.M.; Qian, H.; Oro, C.; Abogadie, F.; Delbridge, L.M.; Thomas, W.G. Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles. Cell Signal. 2011, 23, 1767–1776. [CrossRef] [PubMed]
5. Schelshorn, D.; Joly, F.; Mutel, S.; Hampe, C.; Breton, B.; Mutel, V.; Lutjens, R. Lateral allosterism in the glucagon receptor family: Glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Mol. Pharmacol. 2012, 81, 309–318. [CrossRef] [PubMed]
6. Mustafa, S.; See, H.B.; Seeger, R.M.; Armstrong, S.P.; White, C.W.; Ventura, S.; Ayoub, M.A.; Pfleger, K.D. Identification and profiling of novel alpha1A-adrenoceptor-CXC chemokine receptor 2 heteromer. J. Biol. Chem. 2012, 287, 12952–12965. [CrossRef]
7. Watts, A.O.; van Lipzig, M.M.; Jaeger, W.C.; Sebee, R.M.; van Zwan, M.; Vinet, J.; van der Lee, M.M.; Siderius, M.; Zaman, G.J.; Boddeke, H.W.; et al. Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes. Br. J. Pharmacol. 2013, 168, 1662–1674. [CrossRef]
8. Ayoub, M.A.; Zhang, Y.; Kelly, R.S.; See, H.B.; Johnstone, E.K.; McCall, E.A.; Williams, J.H.; Kelly, D.J.; Pfleger, K.D. Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease. PLoS ONE 2015, 10, e0119803. [CrossRef]
9. Toth, A.D.; Gyombolai, P.; Szalai, B.; Varnai, P.; Turu, G.; Hunyady, L. Angiotensin type 1A receptor regulates β-arrestin1/2 by the Angiotensin II Type I and Prostaglandin F2α Receptor Dimer. Front. Endocrinol. 2019, 10, 162. [CrossRef] [PubMed]
12. Ayoub, M.A.; See, H.B.; Seerer, R.M.; Armstrong, S.P.; Pfleger, K.D. Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology. *PLoS ONE* **2013**, *8*, e64672. [CrossRef] [PubMed]

13. Susec, M.; Sencanski, M.; Glisic, S.; Veljkovic, N.; Pedersen, C.; Drinovic, L.; Stojan, J.; Nöhr, J.; Vrecl, M. Functional characterization of β2-adrenergic and insulin receptor heteromers. *Neuropharmacology* **2019**, *152*, 78–89. [CrossRef]

14. O’Brien, S.L.; Johnstone, E.K.M.; Devost, D.; Conroy, J.; Reichelt, M.E.; Purdue, B.W.; Ayoub, M.A.; Kawai, T.; Inoue, A.; Eguchi, S.; et al. BRET-based assay to monitor EGFR transactivation by the AT1R reveals Gq/11 protein-independent activation and AT1R-EGFR complexes. *Biochem. Pharmacol.* **2018**, *158*, 232–242. [CrossRef] [PubMed]

15. Kilpatrick, L.E.; Alcobia, D.C.; White, C.W.; Peach, C.J.; Glenn, J.R.; Zimmerman, K.; Kondrashov, A.; Pfleger, K.D.G.; Ohana, R.F.; Roberts, M.B. et al. Complex Formation between VEGFR2 and the beta2-Adrenoceptor. *Cell Chem. Biol.* **2019**, *26*, 830–841 e839. [CrossRef] [PubMed]

16. Pickering, R.J.; Tikellis, C.; Rosado, C.J.; Tsorotes, D.; Dimitropoulos, A.; Smith, M.; Huet, O.; Seeber, R.M.; Abbayawardana, R.; Johnstone, E.K.; et al. Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. *J. Clin. Investig.* **2019**, *129*, 406–421. [CrossRef]

17. Jaeger, W.C.; Armstrong, S.P.; Hill, S.J.; Pfleger, K.D.G. Biophysical Detection of Diversity and Bias in GPCR Function. *Front. Endocrinol.* **2014**, *5*, 26. [CrossRef]

18. Stoddart, L.A.; Johnstone, E.K.M.; Wheal, A.J.; Goulding, J.; Robers, M.B.; Machleidt, T.; Wood, K.V.; Hill, S.J.; Pfleger, K.D.G. Application of BRET to monitor ligand binding to GPCRs. *Nat. Methods* **2015**, *12*, 661–663. [CrossRef]

19. Ali, A.; Johnstone, E.K.M.; Baby, B.; See, H.B.; Song, A.; Rosengren, K.J.; Pfleger, K.D.G.; Ayoub, M.A.; Vijayan, R. Insights into the Interaction of LVV-Hemorphin-7 with Angiotensin II Type 1 Receptor. *Int. J. Mol. Sci.* **2020**, *22*, 209. [CrossRef]

20. Soave, M.; Stoddart, L.A.; Brown, A.; Woolard, J.; Hill, S.J. Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human beta1-adrenoceptor expressed in HEK-293 cells. *Pharmacol. Res. Perspect.* **2016**, *4*, e00250. [CrossRef]

21. White, C.W.; Johnstone, E.K.M.; See, H.B.; Pfleger, K.D.G. NanoBRET ligand binding at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing. *Cell Signal.* **2019**, *54*, 27–34. [CrossRef]

22. Dale, N.C.; Johnstone, E.K.M.; White, C.W.; Pfleger, K.D.G. NanoBRET: The Bright Future of Proximity-Based Assays. *Front. Bioeng. Biotechnol.* **2019**, *7*, 56. [CrossRef] [PubMed]

23. Stoddart, L.A.; White, C.W.; Nguyen, K.; Hill, S.J.; Pfleger, K.D.G. Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding. *Br. J. Pharmacol.* **2016**, *173*, 3028–3037. [CrossRef] [PubMed]

24. Barki-Harrington, L.; Luttrell, L.M.; Rockman, H.A. Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist: A functional role for receptor-receptor interaction in vivo. *Circulation* **2003**, *108*, 1611–1618. [CrossRef] [PubMed]

25. Hammad, M.M.; Dupre, D.J. Chaperones contribute to G protein coupled receptor oligomerization, but do not participate in assembly of the receptor with the receptor signaling complexes. *J. Mol. Signal.* **2010**, *5*, 16. [CrossRef] [PubMed]

26. AbdAlla, S.; Lother, H.; Abdel-tawab, A.M.; Quitterer, U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. *J. Biol. Chem.* **2001**, *276*, 39721–39726. [CrossRef]

27. Rivas-Santisteban, R.; Rodriguez-Perez, A.I.; Muñoz, A.; Reyes-Resina, I.; Labandeira-Garcia, J.L.; Navarro, G.; Franco, R. Angiotensin AT1 and AT2 receptor heteromer expression in the hemileision rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia. *J. Neuroinflamm.* **2020**, *17*, 243. [CrossRef] [PubMed]

28. Kumar, V.; Knowdle, D.; Gavini, N.; Pulakat, L. Identification of the region of AT2 receptor needed for inhibition of the AT1 receptor-mediated iodoside, 1,4,5-triphosphate generation. *FEBS Lett.* **2002**, *532*, 379–386. [CrossRef]

29. Axelband, F.; Assuncao-Miranda, I.; de Paula, I.R.; Ferrao, F.M.; Dias, J.; Miranda, A.; Miranda, F.; Lara, L.S.; Vieyra, A. Ang-(3-4) increases receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. *Regul. Pept.* **2012**, *173*, 232–242. [CrossRef] [PubMed]

30. Zhang, X.; Wang, G.; Dupre, D.J.; Feng, Y.; Robitaille, M.; Lazartigues, E.; Feng, Y.H.; Hebert, T.E.; Wu, G. Rab1 GTPase and dimerization in the cell surface expression of angiotensin II type 2 receptor. *J. Pharmacol. Exp. Ther.* **2009**, *330*, 109–117. [CrossRef]

31. Yang, J.; Chen, C.; Ren, H.; Han, Y.; He, D.; Zhou, L.; Hopfer, U.; Jose, P.A.; Zeng, C. Angiotensin II AT2 receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. *J. Hypertens.* **2012**, *30*, 1176–1184. [CrossRef] [PubMed]

32. Ferrao, F.M.; Lara, L.S.; Axelband, F.; Dias, J.; Carmona, A.K.; Reis, R.I.; Costa-Neto, C.M.; Vieyra, A.; Lowe, J. Exposure of luminal membranes of LLC-PK1 cells to ANG II induces dimerization of AT1/AT2 receptors to activate SERCA and to promote Ca2+ mobilization. *Am. J. Physiol. Renal. Physiol.* **2012**, *302*, F875–F883. [CrossRef] [PubMed]

33. Dias, J.; Ferrao, F.M.; Axelband, F.; Carmona, A.K.; Lara, L.S.; Vieyra, A. Ang-(3-4) inhibits renal Na+–ATPase in hypertensive rats through a mechanism that involves dissociation of ANG II receptors, heteromers, and PKA. *Am. J. Physiol. Renal. Physiol.* **2014**, *306*, F855–F863. [CrossRef] [PubMed]

34. Inuzuka, T.; Fujioka, Y.; Tsuda, M.; Fujioka, M.; Satoh, A.O.; Horiuichi, K.; Nishide, S.; Nanbo, A.; Tanaka, S.; Ohba, Y. Attenuation of ligand-induced activation of angiotensin II type 1 receptor signaling by the type 2 receptor via protein kinase C. *Sci. Rep.* **2016**, *6*, 21613. [CrossRef] [PubMed]

35. Ferrao, F.M.; Cardoso, L.H.D.; Drummond, H.A.; Li, X.C.; Zhao, J.L.; Gomes, D.S.; Lara, L.S.; Vieyra, A.; Lowe, J. Luminal ANG II is internalized as a complex with AT1R/AT2R heterodimers to target endoplasmic reticulum in LLC-PK1 cells. *Am. J. Physiol. Renal. Physiol.* **2017**, *313*, F440–F449. [CrossRef]
36. Wangler, N.J.; Santos, K.L.; Schadock, I.; Hagen, F.K.; Escher, E.; Bader, M.; Speth, R.C.; Karamyan, V.T. Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site. *J. Biol. Chem.* 2012, 287, 114–122. [CrossRef]

37. Birdsall, N.J. Class A GPCR heterodimers: Evidence from binding studies. *Trends Pharmacol. Sci.* 2010, 31, 499–508. [CrossRef]

38. Rashid, A.J.; So, C.H.; Kong, M.M.; Furtak, T.; El-Ghundi, M.; Cheng, R.; O’Dowd, B.F.; George, S.R. D1-D2 dopamine receptor heterologomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. *Proc. Natl. Acad. Sci. USA* 2007, 104, 654–659. [CrossRef] [PubMed]

39. Fiorentini, C.; Busi, C.; Gorruso, E.; Gott, C.; Spano, P.; Missale, C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. *Mol. Pharmacol.* 2008, 74, 59–69. [CrossRef]

40. Marcellino, D.; Ferre, S.; Casado, V.; Cortes, A.; Le Foll, B.; Mazzola, C.; Drago, F.; Saur, O.; Stark, H.; Soriano, A.; et al. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. *J. Biol. Chem.* 2008, 283, 26016–26025. [CrossRef]

41. Ferre, S.; von Euler, G.; Johansson, B.; Fredholm, B.B.; Fuxe, K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. *Proc. Natl. Acad. Sci. USA* 1991, 88, 7238–7241. [CrossRef] [PubMed]

42. Armstrong, D.; Strange, P.G. Dopamine D2 receptor dimer formation: Evidence from ligand binding. *J. Biol. Chem.* 2001, 276, 22621–22629. [CrossRef] [PubMed]

43. El-Asmar, L.; Springael, J.Y.; Ballet, S.; Andrieu, E.U.; Vassart, G.; Parmentier, M. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. *Mol. Pharmacol.* 2005, 67, 460–469. [CrossRef] [PubMed]

44. Vilardaga, J.P.; Nikolaev, V.O.; Lorenz, K.; Ferrandon, S.; Zhuang, Z.; Lohse, M.J. Conformational cross-talk between alpha2A- and alpha2C-adrenergic and mu-opioid receptors controls cell signaling. *Nat. Chem. Biol.* 2008, 4, 126–131. [CrossRef]

45. Hounouf, C.; Margathe, J.F.; Oueslati, N.; Belhocine, A.; Dupuis, E.; Thomas, C.; Mann, A.; Iliin, B.; Rognan, D.; Trinquet, E.; et al. Time-resolved FRET binding assay to investigate hetero-oligomer binding properties: Proof of concept with dopamine D1/D3 heterodimer. *ACS Chem. Biol.* 2015, 10, 466–474. [CrossRef]

46. Oueslati, N.; Hounouf, C.; Belhocine, A.; Rodriguez, T.; Dupuis, E.; Zwier, J.M.; Trinquet, E.; Pin, J.-P.; Durroux, T. Time-Resolved FRET Screen to Select GPCR Ligand Library. In *G Protein-Coupled Receptor Screening Assays: Methods and Protocols*; Prazeres, D.M.F., Martins, S.A.M., Eds.; Springer New York: New York, NY, USA, 2015; pp. 23–36.

47. Alcobia, D.C.; Ziegler, A.I.; Kondrashov, A.; Comeo, E.; Mistry, S.; Kellam, B.; Chang, A.; Woolard, J.; Hill, S.J.; Sloan, E.K. Visualizing Ligand Binding to a GPCR In Vivo Using NanoBRET. In *iScience*; Elsevier: Amsterdam, The Netherlands, 2018; Volume 6, pp. 280–288.

48. Trifilieff, P.; Rives, M.-L.; Urizar, E.; Piskorowski, R.A.; Vishwasrao, H.D.; Castrillon, J.; Schmass, C.; Slttman, M.; Gullberg, M.; Javitch, J.A. Detection of antigen interactions ex vivo by proximity ligation assay: Endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. *BioTechniques* 2011, 51, 111–118. [CrossRef]

49. Borroto-Escuela, D.O.; Craenenbroeck, K.V.; Romero-Fernandez, W.; Guidolin, D.; Woods, A.S.; Rivera, A.; Haegeaman, G.; Agnati, L.F.; Tarakanov, A.O.; Fuxe, K. Dopamine D2 and D4 receptor heteromerization and its allosteric receptor–receptor interactions. *Biochem. Biophys. Res. Commun.* 2011, 404, 928–934. [CrossRef]

50. Parhamifar, L.; Sime, W.; Yudina, Y.; Vilhardt, F.; Mörgelin, M.; Sjölander, A. Ligand-Induced Tyrosine Phosphorylation of Cysteinyl Leukotriene Receptor 1 Triggers Internalization and Signaling in Intestinal Epithelial Cells. *PLoS ONE* 2010, 5, e14439. [CrossRef]

51. Dacres, H.; Michie, M.; Wang, J.; Pfleger, K.D.; Trowell, S.C. Effect of enhanced Renilla luciferase and fluorescent protein variants on the Forster distance of Bioluminescence resonance energy transfer (BRET). *Biochem. Biophys. Res. Commun.* 2012, 425, 625–629. [CrossRef] [PubMed]

52. Weihs, F.; Wang, J.; Pfleger, K.D.G.; Dacres, H. Experimental determination of the bioluminescence resonance energy transfer (BRET) Förster distances of NanoBRET and red-shifted BRET pairs. *Anal. Chem. Acta* 2020, 6, 100059. [CrossRef]

53. Gurevich, V.V.; Gurevich, E.V. GPCR monomers and oligomers: It takes all kinds. *Trends Neurosci.* 2008, 31, 74–81. [CrossRef] [PubMed]

54. Ayoub, M.A.; Pfleger, K.D. Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization. *Curr. Opin. Pharmacol.* 2010, 10, 44–52. [CrossRef] [PubMed]

55. Ramsay, D.; Carr, I.C.; Pediani, J.; Lopez-Gimenez, J.F.; Thurlow, R.; Fidock, M.; Milligan, G. High-affinity interactions between human alpha1A-adrenoceptor C-terminal splice variants produce homo- and heterodimers but do not generate the alpha1L-adrenoceptor. *Mol. Pharmacol.* 2004, 66, 228–239. [CrossRef] [PubMed]

56. Goin, J.C.; Nathanson, N.M. Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells: Regulation of receptor down-regulation by heterodimerization. *J. Biol. Chem.* 2006, 281, 5416–5425. [CrossRef]

57. Ayoub, M.A.; Levoye, A.; Delagrange, P.; Jockers, R. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. *Mol. Pharmacol.* 2004, 66, 312–321. [CrossRef] [PubMed]

58. Small, K.M.; Schwab, M.R.; Glinka, C.; Theiss, C.T.; Brown, K.M.; Seman, C.A.; Liggett, S.B. Alpha2A- and alpha2C-adrenergic receptors form homo- and heterodimers: The heterodimeric state impairs agonist-promoted GRK phosphorylation and beta-arrestin recruitment. *Biochemistry* 2006, 45, 4760–4767. [CrossRef]